journal article·2020-03-09

Biodegradable Mg Implants Suppress the Growth of Ovarian Tumor

Shuang Qiao, Yongjie Wang, Rui Zan, Hongliu Wu, Yu Sun, Hongzhou Peng, Rui Zhang, Yang Song, Jiahua Ni, Shaoxiang Zhang, Xiaonong Zhang

Publisher page

Abstract

The common treatment of epithelial ovarian cancer is aggressive surgery followed by platinum-based cytotoxic chemotherapy. However, residual tumor cells are resistant to chemotherapeutic drugs during postoperative recurrence. The treatment of ovarian cancer requires breakthroughs and advances. In recent years, magnesium alloy has been widely developed as a new biodegradable material because of its great potential in the field of medical devices. From the degradation products of magnesium, biodegradable magnesium implants have great potential in antitumor. According to the disease characteristics of ovarian cancer, we choose it to study the antitumor characteristics of biodegradable magnesium. We tested the anti-ovarian tumor properties of Mg through both in vivo and in vitro experiments. According to the optical in vivo imaging and relative tumor volume statistics of mice, high-purity Mg wires significantly inhibited the growth of SKOV3 cells in vivo. We find that the degradation products of Mg, Mg2+, and H2 significantly inhibit the growth of SKOV3 cells and promote their apoptosis. Our study suggests a good promise for the treatment of ovarian cancer.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Hydrogen's biological and therapeutic effects · Hydrogen Storage and Materials · Magnesium in Health and Disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Metal Matrix Composites, School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, People’s Republic of China

Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China

Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China

Wallace H Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, United States

Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States

Suzhou Origin Medical Technology Company Ltd., Suzhou 215513, China

Funding

Shanghai Jiao Tong University · Ministry of Science and Technology of the People's Republic of China

References (34)

Show source-provided references
1. 10.3322/caac.2149210.3322/caac.21492 ↗
2. 10.1016/S0140-6736(13)62146-710.1016/S0140-6736(13)62146-7 ↗
3. 10.1200/JCO.2008.19.296310.1200/JCO.2008.19.2963 ↗
4. 10.3322/caac.2144210.3322/caac.21442 ↗
5. 10.1038/srep2173610.1038/srep21736 ↗
6. 10.1016/j.actbio.2015.07.01710.1016/j.actbio.2015.07.017 ↗
7. 10.1016/j.biomaterials.2016.10.01710.1016/j.biomaterials.2016.10.017 ↗
8. 10.1002/adem.20031040510.1002/adem.200310405 ↗
9. 10.1016/s1005-0302(12)60128-510.1016/s1005-0302(12)60128-5 ↗
10. 10.1016/j.jmst.2014.04.01010.1016/j.jmst.2014.04.010 ↗
11. 10.1002/jbm.a.3493310.1002/jbm.a.34933 ↗
12. 10.1684/mrh.2011.028510.1684/mrh.2011.0285 ↗
13. 10.1042/CS2012008610.1042/CS20120086 ↗
14. 10.1016/j.biomaterials.2005.12.03010.1016/j.biomaterials.2005.12.030 ↗
15. 10.1038/s41467-018-06630-210.1038/s41467-018-06630-2 ↗
16. 10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j ↗
17. 10.1200/JCO.1999.17.9.294110.1200/JCO.1999.17.9.2941 ↗
18. 10.1016/j.biomaterials.2015.06.03110.1016/j.biomaterials.2015.06.031 ↗
19. 10.1016/S0140-6736(07)60853-810.1016/S0140-6736(07)60853-8 ↗
20. 10.1016/j.jmst.2013.02.00510.1016/j.jmst.2013.02.005 ↗
21. 10.1039/c4tb01421a10.1039/c4tb01421a ↗
22. 10.1016/j.jmst.2014.03.00410.1016/j.jmst.2014.03.004 ↗
23. 10.1021/acsami.7b1549810.1021/acsami.7b15498 ↗
24. 10.1016/j.jconrel.2008.05.00310.1016/j.jconrel.2008.05.003 ↗
25. 10.1002/(sici)1522-2594(199904)41:4<743::aid-mrm13>3.0.co;2-z10.1002/(sici)1522-2594(199904)41:4<743::aid-mrm13>3.0.co;2-z ↗
26. 10.1016/j.actbio.2014.09.04110.1016/j.actbio.2014.09.041 ↗
27. 10.1016/j.msec.2015.12.04310.1016/j.msec.2015.12.043 ↗
28. 10.1126/science.116630410.1126/science.1166304 ↗
29. 10.1038/nm157710.1038/nm1577 ↗
30. 10.1183/1393003.congress-2017.PA356510.1183/1393003.congress-2017.PA3565 ↗
31. 10.1186/s40170-016-0145-910.1186/s40170-016-0145-9 ↗
32. 10.18632/oncotarget.2113010.18632/oncotarget.21130 ↗
33. 10.1016/j.actbio.2015.04.01110.1016/j.actbio.2015.04.011 ↗
34. 10.1016/j.actbio.2017.08.05110.1016/j.actbio.2017.08.051 ↗